vspВопросы современной педиатрииCurrent Pediatrics1682-55271682-5535Издательство «ПедиатрЪ»vsp-835Research ArticleОБМЕН ОПЫТОМEXCHANGE OF EXPERIENCEОПЫТ ПРИМЕНЕНИЯ ИБАНДРОНОВОЙ КИСЛОТЫ У БОЛЬНЫХ С ТЯЖЕЛЫМ ТЕЧЕНИЕМ РЕВМАТИЧЕСКИХ БОЛЕЗНЕЙ И СИСТЕМНЫМ ОСТЕОПОРОЗОМEXPERIENCE OF TREATMENT WITH IBANDRONIC ACID IN PATIENTS WITH SEVERE RHEUMATOLOGICAL DISEASES AND SYSTEMIC OSTEOPOROSISЛисицинА.О.LisitsynA.O.АлексееваЕ.И.AlexeevaE.I.ПинелисВ.Г.PinelisV.G.БакановМ.И.BakanovM.I.ВалиеваС.И.ValievaS.I.БзароваТ.М.BzarovaT.M.Научный центр здоровья детей РАМН, МоскваРоссияScientific Center of Children’s Health, Russian Academy of Medical Sciences, MoscowRussian Federation20101409201591Вопросы современной педиатрии116121Copyright © Лисицин А., Алексеева Е., Пинелис В., Баканов М., Валиева С., Бзарова Т., 20102010Лисицин А., Алексеева Е., Пинелис В., Баканов М., Валиева С., Бзарова Т.Lisitsyn A., Alexeeva E., Pinelis V., Bakanov M., Valieva S., Bzarova T.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://vsp.spr-journal.ru/jour/article/view/835

В статье представлены результаты исследования эффективности и безопасности лечения ибандроновой кислотой 21 ребенка с ревматическими болезнями и тяжелым системным остеопорозом. Лечение ибандронатом в течение 48 нед обеспечило статистически значимое повышение минеральной плотности костной ткани, уменьшение интенсивности болевого синдрома, снижение сывороточной концентрации маркера костной резорбции — С-концевого телопептида. Развития повторных компрессионных переломов позвонков и костей периферического скелета на фоне лечения препаратом не зафиксировано.

Ключевые слова: дети, ревматические болезни, остеопороз, лечение, бисфосфонаты, ибандроновая кислота.(Вопросы современной педиатрии. 2010;9(1):116-121)

This article presents the results of a study of effectiveness and safety of ibandronic acid in 21 children with rheumatologic diseases and severe systemic osteoporosis. The treatment with ibandronic acid during 48 weeks provided statistically significant increase of mineral density of bones, decrease of pain intensity, lessening of serum concentration of bone resorption marker — C-terminal telopeptide. The development of repeated compressive fractures of vertebrae and bones of peripheral skeleton at the time of treatment with this medication was not detected. 

Key words: children, rheumatological diseases, osteoporosis, treatment, bifosfonates, ibandronic acid.(Voprosy sovremennoi pediatrii — Current Pediatrics. 2010;9(1):116-121)

ReferencesCassidy J.T., Petty R.E., Laxer R.M., Lindsley C.B. Textbook of Pediatric Rheumatology. 5th ed. Philadelphia: W.B. Saunders. 2005.Cassidy J.T., Petty R.E., Laxer R.M., Lindsley C.B. Textbook of Pediatric Rheumatology. 5th ed. Philadelphia: W.B. Saunders. 2005.Алексеева Е.И. Ревматические болезни и их влияние на качество жизни детей и их семей. Качество жизни. Медицина. 2008; 1: 14–17.Алексеева Е.И. Ревматические болезни и их влияние на качество жизни детей и их семей. Качество жизни. Медицина. 2008; 1: 14–17.Fleurence R.L., Iglesias C.P., Johnson J.M. The cost effectiveness of bisphosphonates for the prevention and treatment of osteoporosis: a structured review of the literature. Pharmacoeconomics. 2007; 25 (11): 913–933.Fleurence R.L., Iglesias C.P., Johnson J.M. The cost effectiveness of bisphosphonates for the prevention and treatment of osteoporosis: a structured review of the literature. Pharmacoeconomics. 2007; 25 (11): 913–933.Compston J. Clinical and therapeutic aspects of osteoporosis. Eur. J. Radiol. 2009; 71 (3): 388–391.Compston J. Clinical and therapeutic aspects of osteoporosis. Eur. J. Radiol. 2009; 71 (3): 388–391.Geusens P. Osteoporosis: clinical features. Minerva Med. 2008; 99 (2): 167–175.Geusens P. Osteoporosis: clinical features. Minerva Med. 2008; 99 (2): 167–175.Brufsky A.M. Cancer treatment-induced bone loss: pathophysiology and clinical perspectives. Oncologist. 2008; 13 (2): 187–195.Brufsky A.M. Cancer treatment-induced bone loss: pathophysiology and clinical perspectives. Oncologist. 2008; 13 (2): 187–195.Di Munno O., Delle Sedie A. Effects of glucocorticoid treatment on focal and systemic bone loss in rheumatoid arthritis. J. Endocrinol. Invest. 2008; 31 (7): 43–47.Di Munno O., Delle Sedie A. Effects of glucocorticoid treatment on focal and systemic bone loss in rheumatoid arthritis. J. Endocrinol. Invest. 2008; 31 (7): 43–47.Wells G.A., Cranney A., Peterson J. et al. Alendronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women. Cochrane Database Syst. Rev. 2008; 23(1): CD001155.Wells G.A., Cranney A., Peterson J. et al. Alendronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women. Cochrane Database Syst. Rev. 2008; 23(1): CD001155.Haорis S.T., Blumentals W.A., Miller P.D. Ibandronate and the risk of non-vertebral and clinical fractures in women with postmenopausal osteoporosis: results of a meta-analysis of phase III studies. CuОР Med. Res. Opin. 2008; 24 (1): 237–245.Haорis S.T., Blumentals W.A., Miller P.D. Ibandronate and the risk of non-vertebral and clinical fractures in women with postmenopausal osteoporosis: results of a meta-analysis of phase III studies. CuОР Med. Res. Opin. 2008; 24 (1): 237–245.Russell R.G., Xia Z., Dunford J.E. et al. Bisphosphonates: an update on mechanisms of action and how these relate to clinical efficacy. Ann. N.Y. Acad. Sci. 2007; 17: 209–257.Russell R.G., Xia Z., Dunford J.E. et al. Bisphosphonates: an update on mechanisms of action and how these relate to clinical efficacy. Ann. N.Y. Acad. Sci. 2007; 17: 209–257.Papapoulos S.E. Bisphosphonate actions: physical chemistry revisited. Bone. 2006; 38: 613–616.Papapoulos S.E. Bisphosphonate actions: physical chemistry revisited. Bone. 2006; 38: 613–616.Rudge S., Hailwood S., Horne A. et al. Effects of once-weekly oral alendronate on bone in children on glucocorticoid treatment. Rheumatology (Oxford). 2005; 44 (6): 813–818.Rudge S., Hailwood S., Horne A. et al. Effects of once-weekly oral alendronate on bone in children on glucocorticoid treatment. Rheumatology (Oxford). 2005; 44 (6): 813–818.Bianchi M.L., Cimaz R., Bardare M. et al. Efficacy and safety of alendronate for the treatment of osteoporosis in diffuse connective tissue diseases in children: a prospective multicenter study. Arthritis Rheum. 2000; 43 (9): 1960–1966.Bianchi M.L., Cimaz R., Bardare M. et al. Efficacy and safety of alendronate for the treatment of osteoporosis in diffuse connective tissue diseases in children: a prospective multicenter study. Arthritis Rheum. 2000; 43 (9): 1960–1966.Rudge S., Hailwood S., Horne A. et al. Effects of once weekly oral alendronate on bone in children on glucocorticoid treatment. Rheumatology (Oxford). 2005; 44: 813–818.Rudge S., Hailwood S., Horne A. et al. Effects of once weekly oral alendronate on bone in children on glucocorticoid treatment. Rheumatology (Oxford). 2005; 44: 813–818.Алексеева Е.И., Лисицин А.О., Бзарова Т.М. и др. Эффективность и безопасность терапии алендроновой кислотой при остеопорозе у детей, страдающих юношеским артритом с системным началом. Педиатрическая фармакология. 2009; 1: 101.Алексеева Е.И., Лисицин А.О., Бзарова Т.М. и др. Эффективность и безопасность терапии алендроновой кислотой при остеопорозе у детей, страдающих юношеским артритом с системным началом. Педиатрическая фармакология. 2009; 1: 101.Shaw N.J., Boivin C.M., Crabtree N.J. Intravenous pamidronate in juvenile osteoporosis. Arch. Dis. Child. 2000; 83 (2): 143–145.Shaw N.J., Boivin C.M., Crabtree N.J. Intravenous pamidronate in juvenile osteoporosis. Arch. Dis. Child. 2000; 83 (2): 143–145.Noguera A., Ros J.B., Pavía C.E. et al. Bisphosphonates, a new treatment for glucocorticoid induced osteoporosis in children. J. Pediatr. Endocrinol. Metab. 2003; 16 (4): 529–536.Noguera A., Ros J.B., Pavía C.E. et al. Bisphosphonates, a new treatment for glucocorticoid induced osteoporosis in children. J. Pediatr. Endocrinol. Metab. 2003; 16 (4): 529–536.Steelman J., Zeitler P. Treatment of symptomatic pediatric osteoporosis with cyclic single-day intravenous pamidronate infusions. J. Pediatr. 2003; 142: 417–423.Steelman J., Zeitler P. Treatment of symptomatic pediatric osteoporosis with cyclic single-day intravenous pamidronate infusions. J. Pediatr. 2003; 142: 417–423.Алексеева Е.И., Чистякова Е.Г., Лохматов М.М., Бзарова Т.М. Эффективность эзомепразола в лечении воспалительных заболеваний желудочно-кишечного тракта у детей с ревматическими болезнями. Вопросы современной педиатрии. 2007; 6 (1): 105–107.Алексеева Е.И., Чистякова Е.Г., Лохматов М.М., Бзарова Т.М. Эффективность эзомепразола в лечении воспалительных заболеваний желудочно-кишечного тракта у детей с ревматическими болезнями. Вопросы современной педиатрии. 2007; 6 (1): 105–107.

The authors declare that there are no conflicts of interest present.